INCY Incyte
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Company profile
Ticker
INCY
Exchange
Website
CEO
Paul Friedman
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
INCYTE GENOMICS INC, INCYTE INC, INCYTE PHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
943136539
INCY stock data
()
News
Incyte Announces FDA Has Extended New Drug Application Review Period For Ruxolitinib Cream For Treatment Of Atopic Dermatitis To Sept. 21 To Allow Time To Review Additional Analyses Submitted In Response To FDA's Information Request
11 Jun 21
Incyte, MorphoSys Announce 3-Year Results From Phase 2 L-MIND Study Of Tafasitamab In Combination With Lenalidomide For Treatment Of Relapsed Or Refractory DLBCL
4 Jun 21
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
2 Jun 21
BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients
2 Jun 21
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
1 Jun 21
Press releases
Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
12 Jun 21
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
11 Jun 21
Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)
8 Jun 21
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
4 Jun 21
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
4 Jun 21
Calendar
4 May 21
13 Jun 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Incyte earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Jun 21 | Dhanak Dashyant | Common Stock | Sell | Dispose S | No | Yes | 84.13 | 395 | 33.23K | 26,545 |
| 26 May 21 | Jean Jacques Bienaime | Common Stock | Grant | Aquire A | No | No | 0 | 1,923 | 0 | 10,844 |
| 26 May 21 | Jean Jacques Bienaime | NQSO Common Stock | Grant | Aquire A | No | No | 83.16 | 8,010 | 666.11K | 8,010 |
| 26 May 21 | Clancy Paul J | Common Stock | Grant | Aquire A | No | No | 0 | 1,923 | 0 | 7,017 |
| 26 May 21 | Clancy Paul J | NQSO Common Stock | Grant | Aquire A | No | No | 83.16 | 8,010 | 666.11K | 8,010 |
| 26 May 21 | Dixon Wendy L | Common Stock | Grant | Aquire A | No | No | 0 | 1,923 | 0 | 16,801 |
| 26 May 21 | Dixon Wendy L | NQSO Common Stock | Grant | Aquire A | No | No | 83.16 | 8,010 | 666.11K | 8,010 |
| 26 May 21 | Fouse Jacqualyn A | Common Stock | Grant | Aquire A | No | No | 0 | 1,923 | 0 | 7,433 |
| 26 May 21 | Fouse Jacqualyn A | NQSO Common Stock | Grant | Aquire A | No | No | 83.16 | 8,010 | 666.11K | 8,010 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
90.9% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 463 |
| Opened positions | 54 |
| Closed positions | 78 |
| Increased positions | 161 |
| Reduced positions | 181 |
13F shares |
Current |
|---|---|
| Total value | 21.56B |
| Total shares | 199.9M |
| Total puts | 688.6K |
| Total calls | 811.5K |
| Total put/call ratio | 0.8 |
Largest owners |
Shares | Value |
|---|---|---|
| Baker Bros. Advisors | 32M | $2.6B |
| TROW T. Rowe Price | 30.06M | $2.44B |
| Vanguard | 20.41M | $1.66B |
| BLK Blackrock | 17.68M | $1.44B |
| Wellington Management | 12.95M | $1.05B |
| STT State Street | 8.35M | $678.71M |
| Capital International Investors | 5.5M | $447.19M |
| Renaissance Technologies | 4.9M | $398.12M |
| Dodge & Cox | 4.32M | $350.87M |
| Geode Capital Management | 3.38M | $274.26M |
Financial report summary
?Competition
Geron • CTI BioPharma • Exelixis • Curis • Infinity Pharmaceuticals • Lumos Pharma • Medicinova • Sierra Oncology • AVEO Pharmaceuticals • AnaptysBioManagement Discussion
- We recorded net income of $53.5 million and basic and diluted net income per share of $0.24 for the three months ended March 31, 2021, as compared to net loss of $720.6 million and basic and diluted net loss per share of $3.33 in the corresponding period in 2020.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AAD, Academy, adjacent, area, ASH, BAT, biliary, binary, BOR, BRAVE, broaden, BTC, carefully, constrain, constrained, constraint, context, Defense, demolition, dictated, Division, EC, environment, ESMO, EUA, extracorporeal, firstMIND, fixed, frontMIND, IAI, inMIND, Internet, invasive, MCC, membrane, Motion, myeloma, negligible, Nimble, nonrefundable, outset, oxygen, oxygenation, participatory, pathogenic, peptide, plamotamab, principle, PRV, radio, ready, registration, regrowth, scalp, sNDA, Society, standalone, suboptimal, suspected, television, topMIND, tract, underwritten, worth, XmAb
Removed:
absorption, accurately, aim, analytical, ascertain, baby, backed, bad, block, calendar, capitalization, caution, chemistry, Clarifying, close, cloud, Codification, commencing, computing, Connecting, consecutive, continuity, cornea, decided, deduction, deliver, dry, educational, ending, enterprise, estimation, excretion, eye, fashion, foregoing, fundamental, geography, govern, healthy, IND, indenture, inflamed, institutional, intensity, Interaction, introduction, issuer, Italy, landscape, lengthy, lifetime, metabolism, mild, opening, optimal, overlap, overview, pharmacokinetic, physical, possession, preceding, pregnancy, pregnant, proactive, proceed, proceeding, prospective, qualifying, remote, resolution, retina, retrospective, satisfying, scheduled, Securing, sequential, serve, software, sponsor, stability, staffed, statistical, steering, stockholder, Subtopic, supervision, supportable, sweeping, tackle, title, tolerance, toxicity, trading, translocated, unacceptable, unborn, uncollected, voluntarily, Wisconsin, women
Financial reports
10-Q
2021 Q1
Quarterly report
4 May 21
10-K
2020 FY
Annual report
9 Feb 21
10-Q
2020 Q2
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
13 Feb 20
10-Q
2019 Q3
Quarterly report
29 Oct 19
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
30 Apr 19
10-K
2018 FY
Annual report
13 Feb 19
Current reports
8-K
Departure of Directors or Certain Officers
27 May 21
8-K
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
4 May 21
8-K
Amendments to Articles of Incorporation or Bylaws
19 Feb 21
8-K
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs
9 Feb 21
8-K
Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
5 Nov 20
8-K
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
4 Aug 20
8-K
Departure of Directors or Certain Officers
27 May 20
8-K
Departure of Directors or Certain Officers
14 May 20
8-K
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs
5 May 20
8-K
Departure of Directors or Certain Officers
20 Apr 20
Registration and prospectus
S-8
Registration of securities for employees
11 Jun 21
S-8
Registration of securities for employees
15 Jun 20
S-8
Registration of securities for employees
30 Apr 19
S-3ASR
Automatic shelf registration
14 Feb 19
S-8
Registration of securities for employees
24 May 18
424B2
Prospectus for primary offering
10 Sep 17
424B3
Prospectus supplement
7 Sep 17
424B7
Prospectus with selling stockholder info
9 Mar 17
S-8
Registration of securities for employees
16 Jun 16
S-8
Registration of securities for employees
16 Jun 16
Proxies
DEFA14A
Additional proxy soliciting materials
14 May 21
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DEF 14A
Definitive proxy
16 Apr 21
DEFA14A
Additional proxy soliciting materials
14 May 20
PX14A6G
Letter to shareholders
24 Apr 20
DEF 14A
Definitive proxy
20 Apr 20
DEFA14A
Additional proxy soliciting materials
22 Apr 19
PX14A6G
Letter to shareholders
1 Apr 19
DEF 14A
Definitive proxy
21 Mar 19
DEF 14A
Definitive proxy
13 Mar 18
Other
UPLOAD
Letter from SEC
12 Apr 20
CORRESP
Correspondence with SEC
6 Apr 20
UPLOAD
Letter from SEC
24 Mar 20
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
22 May 18
CT ORDER
Confidential treatment order
25 Feb 18
Ownership
4
INCYTE / Dashyant Dhanak ownership change
3 Jun 21
4
INCYTE / JULIAN BAKER ownership change
28 May 21
4
INCYTE / Katherine A High ownership change
28 May 21
4
INCYTE / EDMUND HARRIGAN ownership change
28 May 21
4
INCYTE / JACQUALYN A FOUSE ownership change
28 May 21
4
INCYTE / WENDY L DIXON ownership change
28 May 21
4
INCYTE / Paul J Clancy ownership change
28 May 21
4
INCYTE / JEAN JACQUES BIENAIME ownership change
28 May 21
SC 13D/A
INCYTE / BAKER BROS. ADVISORS ownership change
18 May 21
4
INCYTE / JULIAN BAKER ownership change
18 May 21
Patents
APP
Utility
Benzothiazole Compounds and Uses Thereof
10 Jun 21
Inventors: Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
APP
Utility
Derivatives of an FGFR Inhibitor
10 Jun 21
The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
APP
Utility
Tricyclic Heterocycles As FGFR Inhibitors
10 Jun 21
Inventors: Matthew S. McCammant, Evan Styduhar, Oleg Vechorkin, Robert Swyka, Wenqing Yao
APP
Utility
Heteroaryl Amide Compounds As Sting Activators
3 Jun 21
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
APP
Utility
Combination Therapy Comprising an ALK2 Inhibitor and a JAK2 Inhibitor
27 May 21
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
Transcripts
2021 Q1
Earnings call transcript
4 May 21
2020 Q4
Earnings call transcript
9 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
4 Aug 20
2020 Q1
Earnings call transcript
5 May 20
2019 Q4
Earnings call transcript
13 Feb 20
2019 Q3
Earnings call transcript
29 Oct 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
30 Apr 19
2018 Q4
Earnings call transcript
14 Feb 19
Reddit threads
Daily Discussion Thread - May 4th, 2021
4 May 21
Daily Discussion Thread - May 3rd, 2021
3 May 21
Viatris (VTRS) recommended as one of 5 v undervalued Pharma stocks in Barrons today
21 Apr 21
Stocks under $75 for the wheel
12 Apr 21
50 tickers in the S&P 500 are at least 15% below their 52w highs. If you put equal capital in all of them, you'd probably be green
6 Apr 21
Vlad's testimony in a nutshell
19 Feb 21
stocks I like - for the hedge funds buying tech to track this
19 Feb 21
PLTR 440k YOLO - Holding since November and now loaded up on LEAPS 🚀
19 Feb 21
Palantir (PLTR) & What It Does
19 Feb 21
PLTR up 7% premarket. Also, the number of wsb comments on a stock relative to GME comments is apparently an analyst metric. 🍌
19 Feb 21